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Kerstin Lindblad-Toh2,17, Lars Rönnblom3, Marie Wahren-Herlenius 1 and
Gunnel Nordmark 3
Abstract
Objectives. Clinical presentation of primary Sjögren’s syndrome (pSS) varies considerably. A shortage of
evidence-based objective markers hinders efficient drug development and most clinical trials have failed to reach
primary endpoints.
Methods. We performed a multicentre study to identify patient subgroups based on clinical, immunological and
genetic features. Targeted DNA sequencing of 1853 autoimmune-related loci was performed. After quality control,
918 patients with pSS, 1264 controls and 107 045 single nucleotide variants remained for analysis. Replication was
performed in 177 patients with pSS and 7672 controls.
Results. We found strong signals of association with pSS in the HLA region. Principal component analysis of clinical
data distinguished two patient subgroups defined by the presence of SSA/SSB antibodies. We observed an unprece-
dented high risk of pSS for an association in the HLA-DQA1 locus of odds ratio 6.10 (95% CI: 4.93, 7.54, P¼2.21062) in
the SSA/SSB-positive subgroup, while absent in the antibody negative group. Three independent signals within the MHC
were observed. The two most significant variants in MHC class I and II respectively, identified patients with a higher risk
of hypergammaglobulinaemia, leukopenia, anaemia, purpura, major salivary gland swelling and lymphadenopathy.
Replication confirmed the association with both MHC class I and II signals confined to SSA/SSB antibody positive pSS.
Conclusion. Two subgroups of patients with pSS with distinct clinical manifestations can be defined by the pres-
ence or absence of SSA/SSB antibodies and genetic markers in the HLA locus. These subgroups should be con-
sidered in clinical follow-up, drug development and trial outcomes, for the benefit of both subgroups.
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Primary Sjögren’s syndrome (pSS) is a systemic auto-
immune disease that predominantly affects women
[1, 2]. Patients are classified as having pSS when fulfill-
ing internationally accepted criteria, but the clinical pres-
entation varies considerably [3, 4]. While sicca
symptoms, with dryness of the eyes and mouth, pain,
and fatigue are common, some patients present with
extra-glandular manifestations such as arthritis, purpura
or interstitial lung disease. Additionally, immune-variables
differ substantially among the patients. The typical
disease-related autoantibodies against SSA and SSB are
found in 70% and 45% of patients, respectively, and in
some a mild leukopenia or hypergammaglobulinaemia
may be detected [5]. Given the heterogeneity in clinical
presentation of what is currently referred to as pSS,
selecting patients and evaluating outcomes in clinical tri-
als has proven difficult. A recent study suggested
patient-reported outcome measures to classify patients
with pSS into different subtypes [6]. Variation in clinical
manifestations or outcome based on presence or ab-
sence of particular biomarkers has also been highlighted
[1, 7]. However, patient-reported symptoms and some
biomarkers may vary over time and these approaches
do not take into account possible underlying genetic
predisposition for different clinical subgroups.
During the past decade, genetic association studies
have revealed several loci linked to pSS (reviewed in
[8, 9]). The most prominent associations are with var-
iants in the HLA region, but associations have also been
found with single-nucleotide polymorphisms (SNPs) in
or around other genes with immunological functions
[10–13]. However, the impact of many of these
Graphical Abstract
Rheumatology key messages
. Clinical data analysis provides evidence for two subgroups of primary Sjögren’s syndrome best defined by SSA/
SSB antibodies.
. Signals within the HLA region are unique to patients with SSA/SSB autoantibodies.
. Genetic markers of the HLA locus and SSA/SSB autoantibodies define two distinct subgroups of primary
Sjögren’s syndrome.
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polymorphisms in pSS pathogenesis has not been
studied, nor how differences in the clinical presentation
relate to genetic variants.
Using a large set of cases of well-characterized patients
with pSS, the aim of this study was to investigate if genet-
ic heterogeneity and variation in clinical phenotypes repre-
sent different disease subtypes that may require
distinction for both diagnosis and treatment. We
sequenced >1800 autoimmunity-related gene loci in nearly
1000 patients from Sweden and Norway and analysed
clinical features of the patients focusing on immunological
manifestations intersected with genetic associations.
Methods
Patients and controls
A total of 982 patients with pSS from Sweden and
Norway, and 1342 healthy blood donors and population
controls were included in the study (Supplementary
Table S1, available at Rheumatology online). All patients
fulfilled the American European Consensus Group
(AECG) criteria for pSS [4] (Table 1 and Supplementary
Table S2, available at Rheumatology online). For
replication, an independent set of 177 patients with pSS
from Sweden and Norway and 7672 controls (n¼ 918
from the Prospective Investigation of the Vasculature in
Uppsala Seniors (PIVUS) and n¼6754 from the Swedish
Twin Registry (STR) were included (Supplementary
Table S1, available at Rheumatology online) [14, 15]).
The study was approved by the local ethics committees
and patients gave written informed consent.
Targeted sequencing, genotyping and quality control
A sequence capture array was designed to target 1853
genes including their coding and regulatory regions, cover-
ing 32.2 Mbp (see Supplementary Materials and methods,
Supplementary Table S3 and Supplementary Fig. S1,
available at Rheumatology online). Genes were selected
based on their known role in immunological processes, in-
flammation and autoimmune diseases. Sequencing libra-
ries were prepared from genomic DNA, hybridized (Roche
NimbleGen, Basel, Switzerland) and then sequenced with
100-bp paired-end reads using an Illumina HiSeq 2500
(Illumina, Inc., San Diego, CA, USA). Samples with a mean
target coverage of <10 were excluded. A set of bi-allelic
single nucleotide variants (SNVs) was generated with call
rate 90% for SNVs and 80% for samples. Population
TABLE 1 Clinical characteristics of patients with primary Sjögren’s syndrome
All patients Anti-SSA/SSB positive Anti-SSA/SSB negative P-valuea
(n 5 982) (n 5 717) (n 5 265)
Females, % 93.1 92.1 95.8 0.037
Age, mean (S.D.), years
At symptom onset 46.2 (14.7) 45.1 (15.1) 49.0 (13.3) 5.0  104
At diagnosis 52.6 (13.7) 51.3 (14.0) 56.1 (12.1) <1  104
Laboratory findings, %
ANA 74.8 85.8 44.9 <1  104
Anti-SSA 70.5 96.5 0.0
Anti-SSB 42.8 58.8 0.0
Anti-SSA and/or anti-SSB 73.0 100 0.0
Anaemia Hb <120 g/l 22.3 26.5 10.9 <1  104
Leukopenia <4.0  109/l 30.5 36.8 13.9 <1  104
Thrombocytopenia <100  109/l 3.7 4.3 2.0 0.15
P-IgG >15 g/l 48.8 59.6 14.5 <1  104
Minor salivary gland biopsies
Focus score, mean (S.D.) 2.4 (2.4) 2.5 (2.6) 2.2 (1.9) 0.04
Germinal centre formations, % 21.8 25.5 14.2 0.013
Extraglandular manifestations, %
Raynaud 29.1 29.1 29.0 0.98
Arthritis 19.4 20.6 16.1 0.12
Purpura 10.7 13.8 2.8 <1  104
Major salivary gland swelling 30.0 32.8 22.6 3.9  103
Lymphadenopathy 9.1 10.5 5.3 0.014
Hypothyreoidism 22.5 21.3 25.4 0.21
Myositis 0.9 1.1 0.5 0.38
Interstitial lung disease 6.8 7.6 4.3 0.12
Interstitial nephritis 3.0 3.3 2.2 0.46
Lymphoma 4.6 5.5 2.3 0.036
Age at lymphoma onset, mean (S.D.), years 57.1 (13.7) 54.5 (12.4) 73.8 (9.0) 8.8  104
aP-value for the comparison between anti-SSA/SSB (anti-SSA and/or anti-SSB) positive and anti-SSA/SSB negative
patients. Continuous variables compared with Student’s unpaired t-test, frequencies with v2 test.
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outliers and related samples were excluded and 918
patients with pSS and 1264 controls remained for
analysis.
The replication set was genotyped on Illumina
OmniExpressExome (cases and PIVUS) and Illumina
OmniExpress (STR). Quality control was performed and
additional variants imputed based on the Haplotype ref-
erence consortium r1.1 (Supplementary Materials and
methods, available at Rheumatology online) [16].
Statistical analysis
Single variant association analysis in the main set of
cases and controls for variants with a minor allele fre-
quency (MAF) of 1% (n¼ 107 045) was performed in
PLINK using a logistic regression model [17]. Experiment-
wide Bonferroni corrected significance was set to
P < 8.7107 after removal of highly correlated SNVs
[57 768 SNVs remaining with linkage disequilibrium (LD)
r2<0.8] and a suggestive significance threshold of
P<1105 was applied. For clinical data, continuous vari-
ables were analysed using Student’s unpaired t-test and
frequencies were compared with v2 unless there were <5
observations, in which case Fisher’s exact test was
applied (Statistica version 13.4.0.14, TIBCO Software Inc.,
Palo Alto, CA, USA). Correlations between clinical varia-
bles were assessed using Spearman’s correlation in
GraphPad Prism 6 (GraphPad Software Inc., La Jolla, CA,
USA) and results plotted in Morpheus (https://software.
broadinstitute.org/morpheus/). Principal component ana-
lysis of clinical data and plotting of results was carried out
in R [18]. Logistic regression analyses of genotypes and
clinical variables were performed using a generalized lin-
ear model and plotted using R. Association analysis for
variants selected for replication was performed in PLINK
using a logistic regression model with the first three popu-
lation stratification principal components as covariates
(Supplementary Materials and methods, available at
Rheumatology online).
Results
Targeted sequencing suggests novel loci and
confirms known genetic variants associated with
primary Sjögren’s syndrome
To map the genetic variability in pSS, targeted
sequencing of coding regions of 1853 immune-related
genes, including their upstream and downstream regu-
latory regions, was performed on samples from patients
with pSS and controls. Our analysis revealed strong
signals of association for pSS in the HLA region, with
the top variant in the HLA-DQA1 locus [rs6933289;
odds ratio (OR) 3.88; 95% CI: 3.22, 4.66;
P¼ 1.4 1046]. Suggestive associations were also
found with variants in the interferon regulatory factor 5-
transportin 3 (IRF5-TNPO3) locus (OR 1.39; 95% CI:
1.22, 1.61; P¼ 1.8 106), as well as in two novel loci
not previously associated with pSS containing the glu-
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95% CI: 1.23, 1.64; P¼1.1 106) and mitogen-acti-
vated protein kinase 2 (MAP2K2) (OR 1.82; 95% CI:
1.43, 2.33; P¼1.7 106) genes (Table 2, Fig. 1A,
Supplementary Fig. S2 and Supplementary Table S4,
available at Rheumatology online).
Clinical features distinguish distinct patient
subgroups identifiable by unique HLA associations
To identify patient subgroups, we used the clinical informa-
tion available for all 982 patients and performed a principal
component analysis (PCA). Interestingly, this approach dis-
tinguished two clinically distinct subgroups of patients.
Regression analysis revealed that the clinical variable best
corresponding to the first principal component (explaining
16.2% of the overall variability in the clinical data) was SSA
and/or SSB (hereafter SSA/SSB) autoantibody status
(Fig. 1B and Supplementary Fig. S3A, available at
Rheumatology online). This was confirmed using k-means
clustering on the PCA results to reveal two groups that
predicted SSA/SSB positivity with 99.3% accuracy
(Supplementary Fig. S3B, available at Rheumatology on-
line). The clinical variables best associated with the second
principal component (explaining 8.35% of the variability in
the clinical data) were the two interrelated variables age at
symptom onset and age at diagnosis (Supplementary Fig.
S3A, C and D, available at Rheumatology online).
Since subgroups within the patients were best defined
by the presence of SSA/SSB autoantibodies, we strati-
fied the patients based on SSA/SSB autoantibody status
and further explored differences in their clinical presen-
tation. Patients positive for SSA/SSB were younger at
disease onset and diagnosis, and presented more fre-
quently with anaemia, leukopenia, and hypergammaglo-
bulinaemia. Further, SSA/SSB antibody positive patients
displayed an increased prevalence of purpura, major
salivary gland swelling, lymphadenopathy and lymph-
oma, showing an overall more severe disease pheno-
type compared with patients negative for both SSA and
SSB autoantibodies (Table 1).
FIG. 1 Genetic association and subgroup analysis of primary Sjögren’s syndrome patients vs controls
(A) Single variant association analysis between 918 pSS cases and 1264 healthy controls. Logistic regression with
minor allele frequency 0.01 and three principal components as covariates. A total of 107 045 variants included after
quality control. Red line indicates the experiment wide Bonferroni cutoff (P¼ 8.7107); blue line represents the sug-
gestive significance threshold (P¼ 1105). (B) PCA of clinical data collected for 982 pSS cases. (C) Single variant
association analysis between anti-SSA/SSB positive patients (dark blue in PCA plot) vs controls. (D) Single variant as-
sociation analysis between anti-SSA and SSB negative patients (light blue in PCA plot) vs controls. PCA: principal
component analysis.
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FIG. 2 HLA associations with primary Sjögren’s syndrome
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As the two identified pSS patient subgroups differed
in their clinical presentation, we explored genetic associ-
ations separately for each of the two groups. When only
including patients positive for SSA/SSB antibodies in the
analysis and comparing them with controls, the associ-
ation with variants in the HLA region was distinctly
stronger compared with the analysis of the whole set of
cases, with an OR as high as 6.1 for the top associated
variant in the HLA-DQA1 region (rs6933289; OR 6.10;
95% CI: 4.93, 7.54; P¼2.2 1062). The association
with variants in the IRF5-TNPO3 locus was also more
prominent (OR 1.52; 95% CI: 1.30, 1.79; P¼7.4108),
while the association with GOT1 remained unchanged
(OR 1.47; 95% CI: 1.25, 1.72; P¼2.4106) and
MAP2K2 did not pass the suggestive significance
threshold of P< 1105 (OR 1.79; 95% CI: 1.35, 2.33;
P¼4.2105) (Table 2, Fig. 1C, Supplementary Fig. S4
and Supplementary Table S5, available at Rheumatology
online).
In contrast, when comparing SSA and SSB autoanti-
body negative patients with controls, surprisingly no as-
sociation with HLA was observed. In fact, no variant
associated with SSA/SSB autoantibody negative pSS
exceeded the suggestive significance threshold of
P<1 105, but two signals near kinesin family member
1B (KIF1B) on chromosome 1 (rs149524751; OR 4.55;
95% CI: 2.32, 8.92; P¼ 1.0 105) and caspase 8
(CASP8) on chromosome 2 (rs17860432; OR 2.75; 95%
CI: 1.74, 4.31; P¼1.2105) nearly reached the sug-
gestive cutoff (Fig. 1D, Supplementary Fig. S5 and
Supplementary Table S6, available at Rheumatology
online).
A case–case analysis between patients positive for
SSA/SSB autoantibodies and patients negative for both
autoantibodies identified rs9273058, a variant down-
stream of HLA-DQA1 (OR 0.28; 95% CI: 0.22, 0.35;
P¼6.11026) as the most significantly associated
variant (Supplementary Fig. S6 and Supplementary
FIG. 2 Continued
Stepwise adjustment for the top associated variants. (A, B) Logistic regression analysis of all patients vs controls (A),
or anti-SSA/SSB positive patients vs controls (B). Second panel after conditioning on rs6933289, bottom panel after
conditioning on rs6933289 and rs7197, with rs3099839 top remaining variant in all cases vs controls, rs2523607 top
remaining variant in anti-SSA/SSB positive vs controls. (C) Unadjusted P-values for all cases vs controls (blue), SSA/
SSB positive vs controls (red), and SSA and SSB negative vs controls (grey). (D) Linkage disequilibrium (r2) between
the variants. (E) Gene regions of the independent HLA variants: HLA-DQA1, HLA-DRA and the HLA-B/MICA/HCP5
locus.
FIG. 3 Correlations between clinical phenotypes and associated variants
(A) Non-parametric correlations between associated genetic variants and clinical variables. The purple scale repre-
sents P-values for the correlation (darker represents more significant), and the blue–red scale represents the correl-
ation coefficient, with darker blue representing stronger negative correlation, and deeper red representing stronger
positive correlation. (B) Logistic regression of different clinical variables with risk allele count for the top associated in-
dependent genetic variants. Red lines represent significant positive associations, blue lines significant negative asso-
ciations. Whiskers indicate 95% CI. OR: odds ratio.
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Table S7, available at Rheumatology online). The HLA-
DQA1 variant most strongly associated with SSA/SSB
positive pSS (rs6933289) remained significantly associ-
ated in the case–case comparison of the two patients
subgroups (OR 4.03; 95% CI: 2.97, 5.47;
P¼3.01019), despite the lower power. This demon-
strates that the association with the HLA region in pSS
is unique to the SSA/SSB autoantibody positive patient
subgroup, providing evidence for distinct genetic aetiol-
ogies in the two groups.
Independent genetic signals within the HLA region
are unique to patients with SSA/SSB autoantibodies
Considering that the associations with variation in the
HLA domain differ between the two pSS subgroups, we
examined the HLA region in more detail. When condi-
tioning on the top variant in the HLA-DQA1 locus
(rs6933289) in the analysis of all patients with pSS vs
controls and SSA/SSB positive cases vs controls, inde-
pendent signals with the highest peak in HLA-DRA
(rs7179) remained (for all patients vs controls, OR 1.85;
95% CI: 1.57, 2.17; P¼ 1.61013; and for SSA/SSB
positive cases vs controls, OR 2.85; 95% CI: 2.34, 3.47;
P¼2.61025), passing the experiment-wide Bonferroni
correction cutoff of P< 8.7 107 (Table 2,
Supplementary Tables S8 and S9, available at
Rheumatology online). Further, conditioning on the top
SNVs from both independent signals revealed a third as-
sociation signal in the HLA-B/MICA/HCP5 locus exceed-
ing the suggestive significance threshold of P<1 105
(rs3099839 in HCP5 for all cases vs controls, OR 2.07;
95% CI: 1.53, 2.80; P¼ 2.4 106; and rs2523607 in
HLA-B for SSA/SSB positive cases vs controls, OR
2.14; 95% CI: 1.59, 2.89; P¼ 6.8 107). These signals
are in high LD (r2¼0.91) (Table 2, Fig. 2A–D,
Supplementary Tables S10 and S11, available at
Rheumatology online). Each of these three independent
HLA signals were more significant in the SSA/SSB posi-
tive cases compared with the analysis of all patients
(Fig. 2C). The LD between the independent signals and
the positions of the nearest genes is depicted in Fig. 2D
and E. Together, these data suggest several independ-
ent HLA associations in pSS, which all are unique to
patients with SSA/SSB autoantibodies.
Genetic variants identify patients with extraglandular
manifestations
To examine the interplay between the three independ-
ently associated HLA genetic variants and clinical pres-
entation, we performed a non-parametric correlation
analysis between risk allele counts and clinical variables
(Fig. 3A and Supplementary Table S12, available at
Rheumatology online). This analysis revealed significant
correlations between HLA-DQA1 (rs6933289) and HCP5
(rs3099839) and a number of clinical variables including
younger age at symptom onset and diagnosis, ANA,
SSA and SSB autoantibodies, hypergammaglobulinae-
mia, leukopenia, anaemia, purpura, major salivary gland
swelling and lymphadenopathy (0.10<q>0.10,
P<0.05). These correlations mirror the grouping accord-
ing to SSA/SSB antibody status previously identified in
the clinical data.
To further examine the associations between geno-
types and phenotypes, we also performed a logistic re-
gression analysis between the top associated variants
and the clinical variables (Fig. 3B). The HLA-DQA1 and
HCP5 risk variants significantly increased the OR of the
clinical variables previously shown to co-occur with
SSA/SSB autoantibodies, emphasizing the phenotype
identified in the SSA/SSB positive patient subgroup. In
contrast, the HLA-DRA risk variant rs7197 was only
associated with an increased OR for SSA and leuko-
penia, and with a significantly reduced OR for hypothy-
roidism. In all, we conclude that carrying the risk alleles
at HLA-DQA1 and HCP5 predicts distinct clinical mani-
festations of pSS and the presence of SSA/SSB
autoantibodies.
Replication analysis in additional Scandinavian
patients and controls
To replicate the MHC class I association at HLA-B/HCP5,
and the suggestive associations with GOT1 and MAP2K2,
an independent set of 177 Scandinavian pSS cases
(n¼ 153 SSA/SSB antibody positive) and 7672 controls
were included. We confirmed the association between HLA
and pSS being confined to the SSA/SSB autoantibody posi-
tive subgroup. The MHC class I association HLA-B
(rs2523607)/HCP5 (rs3099839) replicated in all patients vs
FIG. 4 Comparison of effect sizes for associated variants
in the HLA region
Top variants from Lessard et al. [10] are shown as light
grey circles and variants from Taylor et al. [13] are
depicted as dark grey triangles. Red diamonds repre-
sent SSA and/or SSB positive primary Sjögren’s syn-
drome associations and blue diamonds represent the
full primary Sjögren’s syndrome associations from the
current study. Position on chromosome 6 is shown on
the x-axis and ORs on the y-axis. The nearest genes are
labelled below. OR: odds ratio.
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controls (rs3099839; OR 3.47; 95% CI: 2.74, 4.41;
P¼ 1.6 1024) and SSA/SSB positive patients vs controls
(rs2523607; OR 3.83; 95% CI: 2.98, 4.92; P¼ 5.31026).
There were no significant associations with GOT1
(rs49193219) or MAP2K2 (rs6630), in the analyses of all
patients with pSS or SSA/SSB antibody positive patients vs
controls. The results are presented in Supplementary Table
S13, available at Rheumatology online.
Discussion
pSS is a heterogeneous disease with an apparent need
for biomarkers to identify patient subgroups for monitor-
ing, prognosis, treatment and inclusion in clinical trials.
Using a combination of genetic information and analysis
of extensive clinical information for nearly a thousand
Scandinavian patients, we detected clear signs of
grouping in the patient data, evident in both clinical
manifestations and genetic associations. We found that
pSS with associated variants in the HLA region is unique
to a subgroup of patients, best identified by the pres-
ence of the hallmark SSA/SSB autoantibodies, and that
the top variant is associated with a six times increased
risk of pSS in this group. Further, to the best of our
knowledge, this is the first time a direct correlation be-
tween HLA risk variants and specific clinical features in
patients with pSS has been described.
Notably, we detected clear grouping of the patients,
with SSA/SSB antibodies and age at disease onset and
diagnosis being the factors explaining most of the vari-
ability in the data. Earlier reports confirm the validity of
the observation as patients positive for SSA/SSB anti-
bodies are known to have an earlier disease onset and
present with more systemic extraglandular manifesta-
tions, such as leukopenia, hypergammaglobulinaemia,
purpura, and major salivary gland swelling [1].
Furthermore, in a recent epidemiological study we found
that patients positive for SSA/SSB antibodies are par-
ticularly at increased risk for cardiovascular disease,
highlighting the importance of subgroup stratification in
clinical monitoring and risk assessment [20].
Combining high resolution variant information, to-
gether with the observation of clinical clustering of
patients, we could demonstrate an unprecedented high
odds ratio of 6.10 for developing pSS compared with
the general population in carriers of the associated vari-
ant rs6933289 in the HLA-DQA1 region, when restricting
the analysis to the identified SSA/SSB antibody positive
subgroup. Notably, there was no risk of SSA/SSB anti-
body negative pSS associated with the same genetic
variant. Previous studies in Caucasians have described
OR of different genetic variants of the HLA locus in the
range of 2–3.5, depicted in Fig. 4 [10, 13].
Different strategies in subgrouping patients with pSS
can be applied. A recent study defined four different
subgroups based on patient-reported outcome meas-
ures of levels of pain, dryness, fatigue, depression and
anxiety [6]. The subgroups differed in laboratory param-
eters and gene expression as well as response in
clinical trials in retrospective analysis of pain, dryness
and fatigue scores, and salivary flow measurements.
Our approach of letting clinical data guide subgrouping
of pSS clearly identifies distinct groups also at the gen-
etic level. We believe these two subgroups defined by
the presence or absence of SSA/SSB antibodies,
demarking autoimmune disease processes, need to be
considered before, or in addition to, applying additional
markers for further subgrouping. The genetic differences
are likely to relate to different pathogenic mechanisms,
and this knowledge will be valuable both for continued
efforts in understanding the mechanisms driving devel-
opment of the respective subtypes and for designing
treatment strategies for each group. Further, with an OR
higher than 6 detectable by a single variant, the preci-
sion approaches clinical usability, at least in the popula-
tion studied (Caucasian).
The hitherto few genome-wide association studies
performed in pSS have not stratified patients according
to autoantibodies or clinical manifestations [10, 11, 13].
The association of HLA variants with the presence of
SSA/SSB autoantibodies has previously been described
in several smaller studies including patients of different
ethnicities [21–23]. However, none of these studies
described associations between HLA and clinical fea-
tures, either because the question was not addressed or
possibly because of lack of power [21]. Here we extend
our knowledge by establishing a direct link between
specific HLA risk variants and clinical manifestations.
This implicates that HLA risk variants not only drive the
autoantibody response, but also predict the various dis-
ease manifestations seen in patients with pSS.
In our study we confirmed the association between var-
iants in IRF5 and pSS, previously established in multiple
ethnicities (reviewed in [8, 9]). Additionally, we found
associations with GOT1 and MAP2K2 passing our sug-
gestive significance threshold. The variants near GOT1
are located in the intergenic region between GOT1 and
NKX2-3, a gene encoding a NKX2 homeobox protein, ne-
cessary for marginal-zone B cell development and impli-
cated in lymphomagenesis [24]. This is intriguing given
the increased risk for B cell lymphoma in pSS. Gene var-
iants in GOT1-NKX2-3 have previously been associated
with inflammatory bowel disease [25]. MAP2K2 encodes
a protein kinase not previously associated with auto-
immune diseases. However, we were not able to confirm
these associations in a small independent Scandinavian
pSS set of cases. To clarify the role of GOT1 and
MAP2K2 variants in pSS susceptibility, these results need
confirmation in additional samples.
The mechanisms that explain the high risk of develop-
ing pSS with SSA/SSB autoantibodies in carriers of spe-
cific HLA variants remain to be understood. While the
HLA proteins have their main role in antigen presenta-
tion, many additional genes are encoded within the
locus and understanding which genes, or combination
of genes and their respective variants, drive the auto-
immune reaction will require detailed mechanistic inves-
tigations. The SSA and SSB antigens are RNA-binding
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proteins which together with SSA/SSB autoantibodies
form immune complexes that induce type I IFN produc-
tion, eliciting an immune response [26, 27]. The upregu-
lated expression of IFN-induced genes, i.e. the IFN
signature, is mainly seen in SSA/SSB positive patients,
which is also supported by observations from studies on
epigenetic regulation [28, 29]. These autoantibodies ap-
pear before pSS is clinically apparent [30]. Notably, an
association with HLA class II alleles in patients with dif-
ferent systemic autoimmune diseases and an IFN signa-
ture has been described [31]. Consequently, activation
of the type I IFN system as an aetiopathogenic mechan-
ism for clinical disease in SSA/SSB antibody positive
patients has been proposed, and variants of IRF5 may
amplify this process, while it is likely that other immune
mechanisms operate in the antibody negative subgroup
of patients with pSS [27, 32, 33]. Further studies into the
pathogenic mechanisms behind antibody negative pSS
are warranted, to discover potential therapeutic targets
for this patient subgroup.
Limitations of our study include the low frequency of
certain clinical manifestations and missing data, possibly
precluding some additional associations with SSA/SSB
antibodies or HLA risk variants. Unfortunately, data on
the severity of dryness, pain, fatigue, anxiety or depres-
sion, which are common manifestations in patients with
pSS, were not available. Antibody data were retrieved
from the medical records and analysed according to rou-
tine clinical immunology methods that may have varied
over time, but SSA/SSB antibody status in pSS is stable
through the disease course [34]. The targeted sequencing
approach precludes identification of novel risk genes not
included in the panel. Future studies should aim at whole
genome sequencing to fully elucidate the genetic back-
ground to pSS and its subphenotypes. Strengths of our
study are the large number of patients included, the
homogeneous genetic background, meticulous evaluation
of diagnostic criteria and detailed clinical data collected
in a similar manner by the participating clinicians.
In conclusion, we define two subgroups of patients
with pSS based on HLA association, SSA/SSB antibod-
ies and clinical manifestations, and demonstrate a direct
correlation between HLA risk variants, age of onset and
several clinical features. The SSA/SSB antibody positive
subgroup clearly presents with a systemic autoimmune
disease. In contrast, the patients negative for these anti-
bodies and lacking the HLA-associated genetic features
could be defined as having an organ-specific disease
with less obvious autoimmune features and potentially a
different underlying pathogenesis, not least in terms of
the predisposing genetic makeup. These differences
need to be considered not only during clinical follow-up,
but also in drug development and when designing clinic-
al trials and determining trial outcomes, for the benefit
of all patients with pSS.
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University, Sweden. 10. Solbritt Rantapää-Dahlqvist,
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Genet 2013;45:1284–92.
11 Li Y, Zhang K, Chen H et al. A genome-wide association
study in Han Chinese identifies a susceptibility locus for
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(pSS): a European multicentre study. Ann Rheum Dis
2002;61:398–404.
24 Robles EF, Mena-Varas M, Barrio L et al. Homeobox
NKX2-3 promotes marginal-zone lymphomagenesis by
activating B-cell receptor signalling and shaping lympho-
cyte dynamics. Nat Commun 2016;7:11889.
25 Lu X, Tang L, Li K et al. Contribution of NKX2-3 polymor-
phisms to inflammatory bowel diseases: a meta-analysis
of 35358 subjects. Sci Rep 2015;4:3924.
26 Bodewes ILA, Al-Ali S, van Helden-Meeuwsen CG et al.
Systemic interferon type I and type II signatures in
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27 Båve U, Nordmark G, Lövgren T et al. Activation of the
type I interferon system in primary Sjögren’s syndrome:
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